Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

June 29, 2020June 29, 2020

CellCept, Cyclophosphamide Both Improve Patient-reported Outcomes in SSc-ILD, Phase 2 Data Show

News

CellCept (mycophenolate mofetil) and cyclophosphamide can both improve the health-related quality of life of people with systemic sclerosis-related interstitial lung disease, an analysis from a Phase 2 clinical trial ... Read more

May 11, 2020May 11, 2020

Lenabasum Use Seen to Lessen Inflammation, Fibrosis in Phase 2 dcSSc Trial

News

Treatment with lenabasum is safe and leads to clinically meaningful improvements in people with diffuse cutaneous scleroderma (dcSSc), results from Phase 2 trial show. The therapy is now being ... Read more

April 27, 2020April 27, 2020

Ofev Approved in Europe for SSc-ILD Treatment in Adults

News

The European Commission has approved Ofev (nintedanib) to preserve lung function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD). This decision follows the recent recommendation from the Committee ... Read more

January 8, 2020January 8, 2020

Autoantibodies Linked to Genetic and Environmental Factors in Scleroderma, Study Finds

News

Researchers have zeroed in on autoantibodies that may be linked to distinct human leukocyte antigen (HLA) genes and environmental factors, something that could help explain the high variability of ... Read more

October 25, 2019October 25, 2019

IFNL3 Gene Variant Linked to High Risk of PF in Scleroderma Patients, Study Finds

News

A recently discovered variant of the IFNL3 gene increases the risk of pulmonary fibrosis (PF) in people with scleroderma, a study reveals. In contrast, no such link was found ... Read more

September 23, 2019September 23, 2019

Processa Enters Agreement to Develop HT-100 as Possible Fibrotic Disease Treatment

News

Processa Pharmaceuticals announced it has entered into a global licensing agreement with Akashi Therapeutics to possibly develop and market HT-100, Akashi’s candidate to treat diseases associated with tissue fibrosis ... Read more

August 23, 2019August 23, 2019

Vasodilators and Aspirin May Protect Hearts of Systemic Scleroderma Patients, Study Suggests

News

Use of vasodilators — medications that trigger the widening and relaxing of blood vessels — may help to prevent heart problems in people with systemic scleroderma, a study suggests. ... Read more

July 19, 2019July 19, 2019

More Accurate Way of Detecting Lung Disease Early in Scleroderma Patients Using HRCT Scans Proposed

News

A new computerized method to analyze high resolution computed tomography (HRCT) scans may help in identifying interstitial lung disease at early stages in scleroderma patients, the research team that developed it ... Read more

April 17, 2019April 17, 2019

Epigenetic Changes May Be Involved in Scleroderma Development, Study Says

News

Epigenetic changes — chemical modifications in DNA that affect gene expression (the process by which information within a gene gives rise to a functional product) — may be involved ... Read more

Pin It on Pinterest